University of Lyon, Claude Bernard Lyon 1 University, Department of Anaesthesia and Intensive Care, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
Eur J Anaesthesiol. 2010 Jul;27(7):653-9. doi: 10.1097/EJA.0b013e3283396341.
The aim of the present study was to determine the dosage of remifentanil that must be added to thiopental 5 mg kg(-1) to provide excellent intubating conditions in 95% of patients.
Sixty-eight premedicated female American Society of Anesthesiologists class 1 and 2 patients were randomly allocated to four remifentanil dose groups (3, 4, 5 or 6 microg kg(-1)). Induction of anaesthesia was performed with a blinded dose of remifentanil infused over 60 s, simultaneously coadministered with thiopental 5 mg kg(-1) infused over 20 s; and tracheal intubation was attempted 150 s after the beginning of induction. The intubating conditions were assessed with the Copenhagen score, according to jaw relaxation, resistance to laryngoscope, vocal cord position and movements and reaction to cuff inflation. A probit analysis was performed to calculate the intubating efficient doses (IEDs) of remifentanil in 50 and 95% of patients (IED50 and IED95). Haemodynamic tolerance was also analysed.
The IED95 of remifentanil was 7.8 microg kg(-1) (95% confidence interval 5.9-10.9). Although the maximum decrease in heart rate and mean arterial pressure was less than 30% during induction of anaesthesia, the haemodynamic tolerance of such a relaxant-free protocol for anaesthesia providing excellent intubating conditions in 95% of patients when using remifentanil and thiopental could not be assessed, as the IED95 of remifentanil was more than 6 microg kg(-1).
The dosage of remifentanil providing excellent intubating conditions in 95% of patients when coadministered with thiopental 5 mg kg(-1) in healthy premedicated female patients undergoing elective surgery was more than 7 microg kg(-1). Our results question the feasibility of using thiopental for a relaxant-free protocol for anaesthesia.
本研究旨在确定瑞芬太尼的剂量,使其与硫喷妥钠 5mg/kg 联合应用时,95%的患者能够达到理想的插管条件。
68 例美国麻醉医师协会(ASA)分级Ⅰ级和Ⅱ级的择期手术的女性患者,随机分为四组,分别接受瑞芬太尼 3、4、5 或 6μg/kg 的剂量。用盲法输注瑞芬太尼 60s,同时输注硫喷妥钠 5mg/kg 20s 诱导麻醉;诱导后 150s 尝试进行气管插管。插管条件用哥本哈根评分法进行评估,根据下颌松弛、喉镜抵抗、声带位置和运动以及充气套囊反应进行评分。采用概率单位分析计算瑞芬太尼 50%和 95%患者有效剂量(IED50 和 IED95)。还分析了血流动力学耐受性。
瑞芬太尼的 IED95 为 7.8μg/kg(95%置信区间 5.9-10.9)。虽然麻醉诱导期间心率和平均动脉压最大下降小于 30%,但由于瑞芬太尼和硫喷妥钠联合应用时,使 95%的患者达到理想插管条件的这种无肌松药的麻醉方案的 IED95 超过 6μg/kg,无法评估其血流动力学耐受性。
在健康的术前女性择期手术患者中,与硫喷妥钠 5mg/kg 联合应用时,瑞芬太尼的剂量超过 7μg/kg 时,可使 95%的患者达到理想的插管条件。我们的结果对使用硫喷妥钠作为无肌松药麻醉方案的可行性提出了质疑。